Search Results for: DNA VACCINES MARKET DNA Vaccines
Kevin James, Shalini Dewan, MS, and Jon Evans, MBA, say the global market for DNA vaccines is estimated at $305.3 million for 2014 and is forecast to grow at a stellar 54.8% compound annual growth rate (CAGR) to reach $2.7 billion by 2019.
Global Market for DNA Vaccines to Reach $2.7 Billion August 25, 2014The vaccine industry is rapidly changing from a mostly empirical approach to a rational design approach. Rapid developments in molecular...
Global Market for DNA Vaccines to Reach $2.7 Billion August 21, 2014The vaccine industry is rapidly changing from a mostly empirical approach to a rational design approach. Rapid developments in molecular...
Univercells Acquires SynHelix, Entering Into Synthetic Biology & the Race to Next-Generation DNA Synthesis January 6, 2022
Univercells S.A. (Univercells) recently announced its acquisition of SynHelix, a biotechnology company that aims to debottleneck biotherapeutics development through an unprecedented robust, scalable, and….
Catalent Acquires Additional Facility at its Gosselies, Belgium, Campus for Commercial-Scale Plasmid DNA Manufacturing May 6, 2021
Catalent and Promethera Biosciences recently announced that Catalent has acquired Promethera’s cell therapy manufacturing subsidiary, Hepatic Cell Therapy Support SA (HCTS), including its….
AnGes & Brickell Biotech Announce Collaboration Agreement for the Development of a Novel DNA Vaccine Candidate for COVID-19 September 9, 2020
AnGes, Inc. recently announced a collaboration agreement with Brickell Biotech, Inc. through which Brickell has the right to develop AnGes’ proprietary….
PROTEIN THERAPEUTICS MARKET – Technology Advances Spur Market Growth of Protein Therapies November 7, 2016
Laurie L. Sullivan and Shalini S. Dewan, BCC Research Analysts, believe with the advent of genetic engineering and recombinant DNA technology, it is now possible to produce a wide variety of human proteins, and that these novel technologies have lifted the market for therapeutic proteins to new heights.
NIH Using PharmaJet in DNA Vaccine Clinical Trial August 10, 2016PharmaJet recently announced that the National Institutes of Health will use the PharmaJet Stratis needle-free device in a DNA vaccine...
SINGLE-USE MARKET – Rise of Single-Use Technologies & Systems in Biopharmaceuticals November 19, 2015
Kevin James and Shalini S. Dewan of BCC Research believe eliminating the risk of contamination is the greatest challenge faced by manufacturers of biopharmaceuticals, and currently, this requires high-level monitoring of critical manufacturing processes. Single-use technology aids biopharmaceutical manufacturers in overcoming this challenge by reducing or eliminating the need for sterilization between batches, thereby improving operational efficiency.
DNA VACCINE TECHNOLOGY – A Vaccine Breakthrough That Could Change Lives & Enable Vaccine Development Programs August 31, 2015
William Hearl, PhD, asks what if there was the potential for a better and safer treatment for allergies, a less-toxic cancer therapy, or a breakthrough treatment to improve the health of a pet or valuable livestock? What if you could employ a new, patented technology that may make these treatments possible?
SPECIAL FEATURE – Outsourcing Formulation Development & Manufacturing: Understanding Critical Attributes Earlier in Development Leads to a More Robust Drug Product June 1, 2022
Contributor Cindy H. Dubin speaks with industry leaders on how drug sponsors and CDMOs are collaborating earlier, and highlights how third-party contractors are navigating material shortages and how the industry is shifting to address different therapeutic targets and molecules, such as mRNA.
Marc Sauer, PhD, discusses his new position, growth at BIOVECTRA, and how he believes mRNA technologies can best be leveraged to improve the lives of patients.
EXECUTIVE INTERVIEW – Catalent: Developing & Delivering Billions of Doses of Drugs Every Year June 1, 2022
Alessandro Maselli, President and Chief Operating Officer of Catalent, talks about his company’s unique approach to drug development partnerships as he prepares to become the company’s new President and Chief Executive Officer on July 1, 2022.